RGNX
HealthcareREGENXBIO Inc.
$13.40
$-0.17 (-1.25%)
Jan 5, 2026
Price History (1Y)
Analysis
REGENXBIO Inc. (RGNX) is a biotechnology company within the healthcare sector, with a market capitalization of $678.35 million and 353 employees. The company's revenue reached $161.32 million in its most recent quarterly period. The financial health of REGENXBIO Inc. reveals significant challenges. The company reported net income of -$177,915,008, EBITDA of -$139,160,992, and a free cash flow of -$69,017,376. Its gross margin, operating margin, and profit margin are -48.6%, -176.3%, and -110.3%, respectively. Additionally, the company's return on equity (ROE) and return on assets (ROA) are -76.9% and -18.5%, indicating significant losses relative to its equity and assets. The balance sheet shows a debt-to-equity ratio of 166.08 and $274.20 million in cash, offset by $268.14 million in debt. REGENXBIO Inc.'s valuation metrics are mixed. The company's forward price-to-earnings (P/E) ratio is -6.49, indicating that the market has assigned a negative value to its future earnings. However, its revenue growth rate was 22.9% year-over-year in its most recent quarterly period. The dividend yield and payout ratio are not applicable as they are both listed as "N/A".
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Visit website →Key Statistics
- Market Cap
- $678.35M
- P/E Ratio
- N/A
- 52-Week High
- $15.41
- 52-Week Low
- $5.04
- Avg Volume
- 649.34K
- Beta
- 1.07
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 353